Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression
Menée à partir des données d'une enquête réalisée sur la période 2019-2021, cette étude analyse l'association entre un traitement pour des troubles de la santé mentale (dépression ou anxiété) et la participation au dépistage du cancer du sein, du côlon-rectum ou du col de l'utérus
Résumé en anglais
Background: Low participation in cancer screening contributes to a disproportionate burden of cancer morbidity and mortality among adults with mental health (MH) disorders like depression and anxiety. It is unknown whether MH treatment affects screening participation in this population.
Methods: Using the 2019 and 2021 National Health Interview Survey, data from screening-eligible respondents with a history of depression or anxiety were analyzed. Dependent variables include up-to-date screening for breast (BC), cervical (CVC), and colorectal cancer (CRC). Exposures of interest included past year receipt of any MH treatment and delayed or nonreceipt of counseling because of cost. Multivariable logistic regression was used to model associations between MH treatment and screening, controlling for sociodemographic and health care access characteristics.
Results: The prevalence of up-to-date screening was lower for those who did not receive MH treatment than those who did among respondents reporting regular feelings of depression or anxiety (adjusted prevalence ratio [aPR] = 0.83; 95% CI, 0.76–0.91 for BC; aPR = 0.83; 95% CI, 0.77–0.88 for CVC; aPR = 0.78; 95% CI, 0.73–0.84 for CRC) or ever being diagnosed with depression or anxiety (aPR = 0.86; 95% CI, 0.81–0.91 for BC; aPR = 0.87; 95% CI, 0.83–0.91 for CVC; aPR = 0.84; 95% CI, 0.80–0.88 for CRC). BC screening was lower for those who reported delayed or nonreceipt of therapy because of cost than those who did not (aPR = 0.88; 95% CI, 0.78–0.99 among adults with regular feelings of depression or anxiety; aPR = 0.91; 95% CI, 0.83–0.99 among adults ever diagnosed).
Conclusions: MH treatment is associated with increased screening among adults with a history of depression or anxiety. Enhancing MH treatment receipt could reduce the cancer burden in this population.
